Happy to discuss.
Artikel: Heat Biologics: COVID-19 Vaccine Testing Imminent, Many Upcoming Catalysts And Substantial Upside Potential
Heat Biologics announced it would commence preclinical testing for its COVID-19 vaccine this quarter and it is finalizing manufacturing plans. The company also stated that it is applying for grants to support clinical development of this program and are advancing collaboration discussions.
Jeff Wolf, Chief Executive Officer of Heat Biologics, commented during the company’s First Quarter 2020 Business Update:
"We continue to make progress advancing our unique COVID-19 vaccine utilizing our robust gp-96 vaccine platform in collaboration with researchers at University of Miami. We plan to commence preclinical testing for the COVID-19 vaccine this quarter and are finalizing our manufacturing plans, which we believe will help shorten the clinical timeline. Additionally, we are applying for grants to support clinical development of this program and are advancing collaboration discussions.“
Therefore, the company could release a set of good news within the next six weeks, regarding the commencement of preclinical testing for the COVID-19 vaccine, grants to support clinical development and potential collaborations.
Even though these catalysts may be enough to warrant a substantial increase in the company’s stock price, there are more catalysts in the near future.
The company announced that it would present additional HS-110 data in combination with Opdivo® at the upcoming ASCO Conference on May 29 and that it plans to initiate an end of Phase 2 Type B meeting with the FDA.